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Assessing Assays
T
he mathematician George Box, recognized worldwide as a
leading developer of statistical methods, once said that
“all models are wrong, but some are useful.” Box’s comment
could be said to apply to the models used in human cancer risk
assessment. Rodent models used to test potential carcinogens
are by their nature “wrong” because they merely simulate the
response of the real target species—humans. James MacDonald,
senior vice president for drug safety and metabolism at the
Schering Plough Research Institute in Kenilworth, New Jersey,
estimates that conventional rodent models correctly predict
human cancer about 50% of the time. “It’s a flip of the coin,”
he says. “A lot of the chemicals that test positive in rodent
assays turn out not to be of concern for humans.”Improving animal models used in can-
cer risk assessment is therefore an
important goal for public health. In
1996, an international group of scien-
tists formed a research consortium dedi-
cated to this task under the auspices of
the International Life Sciences Institute
(ILSI), a Washington, DC–based non-
profit research foundation. Comprising
experts from industry, government, and
academia, the Committee on the
Evaluation of Alternative Models for
Carcinogenicity Testing has just com-
pleted its data collection and review.
The results of the review, reflecting a
six-year commitment and nearly $35
million in collaborative funding, were
published as a monograph in Sep-
tember 2001 in Toxicologic Pathology.
Toxicologists see the publication of the
monograph not only as a milestone for
the project itself, but also as a victory
for collaborative research. “This is a
precedent setting effort,” says Ray
Tennant, director of the NIEHS’s
National Center for Toxicogenomics
(NCT), who served on the committee.
“A broad range of stakeholders came
together to tackle a very complex issue
in public health. I see this as a para-
digm for how other, difficult public
health problems might be resolved in
the future.”
The Problem Assay
To a large extent, the ILSI committee
focused on in vivo alternatives to the
“gold standard” used in cancer risk
assessment for over 30 years: the
chronic two-year rodent bioassay, per-
formed in mice and rats of both sexes.
Briefly, the test involves exposing animals
to varying levels of a given chemical
(beginning with the maximum tolerated
dose, or MTD), sacrificing the animals
once the exposure period has ended,
and then checking their organ systems
for numbers and types of tumors. Two
implicit assumptions govern the test:
that the animal and human responses
will be the same, and that high-dose
effects observed in the laboratory
will also be relevant for ordinary
human exposures.
With advancements in risk assess-
ment, both of these assumptions have
come under scrutiny. Today, toxicolo-
gists acknowledge that, depending on
the chemical, the effect of tumor induc-
tion in animals may be species specific,
with little relevance to humans. In per-
haps the best-known example, the
B6C3F1 mouse used in the two-year
bioassay is highly susceptible to chemi-
cally induced liver tumors, which are
thought to arise from pathways that are
unique to that strain. Scientists also
question the relevance to humans of
rodent tumors obtained only with the
MTD. “If we’re dealing with a situation
in which the likely human exposure is
in the same ballpark, then these [dosing
regimens] may be applicable,” says Jay
Goodman, professor of pharmacology
and toxicology at Michigan State
University in Lansing. “But doses that
are hundreds to thousands of times
higher than normal exposures [such as
those often given during animal testing]
might be carcinogenic simply because
they overwhelm detoxification path-
ways. In these cases, we see tumors
along with gross histopathologic evi-
dence of tissue damage.”
In the face of these shortcomings,
many experts believe the scientific
value of the two-year bioassay is highly
limited—barely worth the investments
in personnel, animals, money, and
time. “All we’re doing with the [two-
year test] is counting tumors,” laments
Samuel Cohen, chair of the Depart-
ment of Pathology and Microbiology at
the University of Nebraska Medical
Center in Omaha. “We need tests that
tell us more about a chemical’s biologi-
cal mode of action, so that we can
be more confident about extrapolating
to humans.”
The Transgenic Alternatives
Transgenic rodent models provided by
advances in molecular biology are wide-
ly seen as the most promising in vivo
alternatives to the two-year rodent
assay. These models are bred with
genetic predispositions that increase
their susceptibility to insult from car-
cinogens and to the rapid development
of cancer. Scientists believe their use
will accelerate cancer testing and pro-
vide important mechanistic insights
into how carcinogens produce tumors.
Five of the six alternative in vivo
models evaluated by the ILSI commit-
tee involve the use of transgenic species:
the rasH2 transgenic mouse, the TgAC
transgenic mouse, the p53 knockout
mouse, the Xpa knockout mouse, and
the p53/Xpa double knockout mouse.
The review also lists one nontransgenic
in vivo alternative, the neonatal mouse
assay, and one in vitro test, the Syrian
hamster embryo assay.
According to Ronald E. Cannon, a
staff scientist at the NCT, each model
expresses a particular cancer-inducing
genetic anomaly. The p53 knockout
mouse is perhaps the best-known exam-
ple. p53 is a tumor suppressor gene
found in all mammalian cells. Under
normal conditions, the gene responds
to certain kinds of DNA damage by ini-
tiating cell death, thereby taking defec-
tive cells out of circulation. Defects in
p53 are a serious health threat, impli-
cated in as many as 50% of all human
cancers. In the transgenic model, scien-
tists intentionally mutate the gene to
“knock out” p53. Without this normal
suppressor, the cells quickly form
tumors under carcinogen exposure.
The committee’s selection of the six
in vivo models was not arbitrary. In
1996, all these alternatives had just
been recommended for cancer testing in
the pharmaceutical industry by the
International Conference on Harmon-
ization of Technical Requirements for
the Registration of Pharmaceuticals for
Human Use (ICH), an independent
group of industry and agency stake-
holders from the United States, Europe,
and Japan. That same year, the ICH
recommendation was also recognized as
guidance by the U.S. Food and Drug
Administration (FDA), which since
that time has accepted transgenic data
from the models as valid in considering
new drug applications.
But despite a willingness to consider
such models by FDA regulators, most
researchers had little experience with
the models and were unsure about how
to use them. It was from this sense of
uncertainty that the ILSI project was
born, says Robinson. “For us to feel
more comfortable with the models, we
felt we needed a broader, more stan-
dardized data set,” she explains. “The
goal of the [review] was to increase our
confidence in the models and also to
identify any special cross-model
nuances that we should be aware of.”
In addition to model selection, the
choice of appropriate compounds for
testing the models was also crucially
important. From an initial list of 60
candidates, 21 nonproprietary agents,
including both pharmaceutical and
industrial chemicals, such as cyclo-
sporin A, dieldrin, and diethylstilbestrol
were ultimately chosen. Each compound
had available mouse and rat data from
the two-year bioassay, an established
toxicology database of in vitro and in
vivo modes of action, and data related to
human exposure and effect. According
to Denise Robinson, executive director
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Sciences Institute, particular emphasis
was placed on suspected nongenotoxic
carcinogens. These are also sometimes
referred to as “rodent-only” carcinogens
because tumors are elicited solely at the
MTD, presumably via strain-specific
mechanisms considered irrelevant to
humans. The selection process also
emphasized a range of biological effects,
including immunosuppression, enzyme
induction, and proliferation of peroxi-
somes (a precursor to tumors).
A key issue considered by the review
committee was what additional mecha-
nistic insights the alternative models
might provide compared with the two-
year assay. For example, suppose a chem-
ical tests positive in one of the two-year
bioassays and negative in a transgenic
model. John E. French, a group leader at
the NIEHS Laboratory of Environ-
mental Carcinogenesis and Mutagenesis,
says this discrepancy would suggest a
“rodent-only”  carcinogen acting
through a species-specific pathway.
Conversely, a positive result in both
models would suggest a potential
human carcinogen, possibly acting via a
specific genetic pathway.
The Results
To reach conclusions with confidence,
scientists must have faith that the trans-
genic models are reliable and accurate.
However, the ILSI data indicate this is
not always possible. According to
Cohen, under the conditions employed
during the tests, the models could not
always distinguish between genotoxic
and nongenotoxic carcinogens, nor did
they identify human carcinogens with a
100% specificity. For example,
estradiol—a known human breast and
endometrium carcinogen—tested nega-
tive in the rasH2, Xpa, and TgAC
models. Based on his review, Cohen
says, “My personal feeling is that it’s
not appropriate to use any of these
models as proof [or negation] of
genotoxicity; the models provided
exceptions in either direction.”
The chief consensus among the
review committee members is that four
of the alternative models might substi-
tute adequately for the two-year mouse
bioassay, but only if the data are con-
sidered as part of an overall “weight-of-
the-evidence” approach that takes
information from multiple sources into
account. These four models are the
p53, Xpa, TgAC, and rasH2 models,
which are considered genetically stable
(meaning the genetic specificity holds
up over successive generations of
breeding), flexible regarding dosing
options (oral, gavage, or dietary), and
able to produce a wide spectrum of
tumors depending upon the type of
chemical exposure. According to
French, summary results from all stud-
ies published to date show that the
accuracy of these models ranged from a
low of 76% in TgAC to 82% in rasH2,
reaching approximately 90% when
results from p53 (for genotoxic car-
cinogens) and rasH2 (for both geno-
toxic and nongenotoxic carcinogens)
were combined.
The researchers emphasize that
alternative carcinogenicity testing para-
digms should continue to rely on the
rodent bioassay in combination with a
single, targeted transgenic model. This
line of reasoning is supported by the
results of a meta-review of all the avail-
able transgenic carcinogenicity testing
data (including that reviewed by ILSI)
by John Pritchard, chief of the NIEHS
Laboratory of Pharmacology and
Chemistry. The results of this review
indicate that, with such a combination,
it was possible to correctly identify all
the known human carcinogens con-
tained in the data set. Results of the
review are being finalized and, accord-
ing to French, will likely be published
in the fall.
Based on its review, the NIEHS has
proposed that in some cases, even the
rat test may be unnecessary. As part of
an alternative testing paradigm for
chemicals at its National Toxicology
Program, the NIEHS will routinely
perform abbreviated studies with trans-
genic mice concurrent with its standard
three-month toxicity screening studies.
The selection of the appropriate model,
Cannon says, will be based on existing
information about the chemical and its
likely genetic target. According to
Cannon, a positive result in the trans-
genic model may be sufficient to identi-
fy a chemical as a human carcinogen
during the screening process. This is
because human carcinogens are consid-
ered to be genotoxic, meaning that can-
cer develops from an interaction
between potentially low levels of the
chemical and DNA, as opposed to can-
cers identified in the two-year bioassay,
which may result from toxic damage to
tissues. “If we get a positive result with-
out any clear-cut evidence of tissue
damage, why would we want to even
run the rat assay?” he asks. Cohen is
more cautious in this respect. “My dif-
ficulty with that is that we are not yet
to the level where a positive result in a
transgenic assay clearly indicates a
human carcinogen,” he says.
Both researchers agree, however,
that substituting alternative models for
the two-year rodent assay will save time
(transgenic models typically require
only 6–9-month exposures) and
expense. “The alternative tests use far
fewer animals,” Cohen explains.
“Although the appropriate numbers are
still debated, it’s currently 15 animals
per dose group versus 50 animals in the
two-year assay. That’s a lot less patholo-
gy to be concerned with.”
Even this reduction continues to be
unacceptable to animal rights activists.
“It’s just more of the same,” says Troy
Seidle, research associate with People
for the Ethical Treatment of Animals in
Toronto, Canada, who insists (contrary
to the beliefs of the ILSI committee
members) that in vitro models like the
ones evaluated by the ILSI committee
are sufficiently predictive of human
carcinogenicity to be useful in a regula-
tory context. “Nothing short of a
nonanimal system will satisfy us, and
we do not believe that reliance on
transgenics provides a step in the right
direction,” he says.
Industry groups, on the other hand,
are encouraged by the movement
toward accepting transgenics in the
cancer testing process. Gerald Long,
senior research scientist with Eli Lily
and Company, says the results of the
ILSI tests have allayed initial fears that
transgenic models may be overly sensi-
tive. “In fact, they appear not to be,” he
says. “The ILSI data combined with the
results of the NIEHS review suggest
that if you pick the appropriate alterna-
tive model, the results are equally as
valid as the old two-species bioassays.”
Cohen concludes that the adequacy
of the transgenic alternatives marks an
important divergence from the two-year
assay, an archaic test that he believes has
been ingrained in the regulatory and
toxicology community for too long.
“My hope is that this is the first step
toward getting rid of the two-year bioas-
say altogether,” he says. “I think this is
what’s going to happen eventually. The
emerging use of these alternatives is the
first step along a path that needs to
start somewhere.”
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